Trial to Evaluate the Efficacy and Safety of Tarceva and Capecitabine in Advanced Pancreatic Cancer Patients
The purpose of this study is to determine efficacy of the treatment with erlotinib in combination with capecitabine in patients with advanced pancreatic cancer.
Metastatic Adenocarcinoma of the Pancreas
DRUG: capecitabine + erlotinib
Objective response rate following RECIST criteria, within study period
Overall survival, within study period|6 months survival rate, within first 6 months after study inclusion|Progression Free Survival (PFS), Time from study inclusion to disease progression|Time to treatment failure (TTF), Time from study inclusion to treatment failure|To determine the index of clinical benefit, at the end of the study|To determine the safety and tolerability of erlotinib and capecitabine when administered together, Within study period
This efficacy will be determined by objective response rate following RECIST criteria.